【摘要】 目的:探讨肺结核合并肺癌抗结核治疗疗效、安全性及停用抗结核药物3月后复发的风险。方法:随机将50例肺结核合并肺癌患者分为两组,甲组给予2HRZE/4HRE,乙组给予2HRZE/7HRE抗结核治疗,观察两组患者疗效、安全性及复发的风险。结果:两组治疗6个月时肺部病灶吸收、痰菌转阴率比较差异均无统计学意义(P>0.05)。但乙组3个月后复发率明显低于甲组(P<0.05)。两组患者治疗中不良反应发生率及安全性比较差异均无统计学意义(P>0.05)。结论:对于肺结核合并肺癌患者,9个月抗结核治疗可明显降低停用抗结核药物3个月后肺结核复发率。更多还原

【Abstract】 Objective:To discuss the efficacy and safety of anti-tuberculous treatment on tuberculosis with lung cancer,and the risk of stopping using anti-tuberculosis drugs three months later.Method:50 cases of patients with tuberculosis combined lung cancer were randomly divided into two groups,the first group was given 2HRZE/4HRE and the second group was given 2HRZE/7HRE anti-tuberculosis treatment,Observed two groups of treatment efficacy,safety and the risk of recurrence.Result:Two groups of treatment for 6 months,the pulmonary lesions absorption,phlegm bacterium turns shade rate had no obvious difference(P>0.05),but the three months recurrence rates in second group significantly lower than the first group(P<0.05).The incidence of adverse reaction and safety in two groups had no significant difference(P>0.05).Conclusion:For pulmonary tuberculosis patients with lung cancer,9 months anti-tb treatment can obviously reduce the recurrence of stopping anti-tb drugs three months later.更多还原